The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

Canadian Guidelines for the Management of Plaque Psoriasis: Overview

(2015) Kim Papp et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Outcome Measures for Psoriasis Severity: A Report from the GRAPPA 2012 Annual Meeting

(2013) K. Callis Duffin et al.   JOURNAL OF RHEUMATOLOGY

Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting

(2013) A. B. Gottlieb et al.   JOURNAL OF RHEUMATOLOGY

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study

(2012) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A?systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis

(2011) Amanda Robinson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

(2010) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

(2010) E Puzenat et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review

(2009) Phyllis I. Spuls et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY